Lupin gets US FDA nod for Somerset facility

Lupin Limited (BSE: 500257) announced it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey. The inspection took place from January 27 to 31, 2025. According to Lupin's Managing Director, Nilesh Gupta, the EIR underscores the company's commitment to quality and compliance and reinforces its position as a leading pharmaceutical manufacturer. Lupin has 15 manufacturing sites and 7 research centers globally.